Clinical trial
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy…
NCT02853305 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT02853305 |
|---|---|
| Title | Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) |
| Official title | A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Urothelial Carcinoma Associated 1 RNA, Human |
| Intervention type | Biological, Drug |
| Interventions | Pembrolizumab, Cisplatin, Carboplatin, Gemcitabine |
| Enrollment | 1,010 |
| Start date | Sep 15, 2016 |
| Primary completion | Apr 29, 2020 |
| Completion | Sep 15, 2022 |
| First posted | Aug 2, 2016 |
| Last update posted | Sep 8, 2023 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: